AI-enabled drug discovery company Xaira launches with $1B
Xaira’s CEO, Dr. Marc Tessier-Lavigne, resigned as president of Stanford University last August due to controversy over inaccuracies discovered in his lab’s scientific papers.
Xaira’s CEO, Dr. Marc Tessier-Lavigne, resigned as president of Stanford University last August due to controversy over inaccuracies discovered in his lab’s scientific papers.
COVER This optical image of Jupiter’s moon Io was taken by the Juno spacecraft during a flyby in February 2024. The surface is covered by…
A-Alpha Bio will use its yeast display platform to accelerate drug discovery against an expanded list of possible biological threats.
Can social work improve health equity? 9 questions for Tami Gouveia
An HIV vaccine candidate triggered low levels of an elusive type of HIV antibodies among a small group of people enrolled in a 2019 clinical…
What determines YOUR health? How to cope with the growing challenges in healthcare ánd health. Lucien Engelen explains his vision on this.
Research suggests selectively blocking the VISTA/LRIG1 axis may be an effective immunotherapeutic approach for the treatment of cancer.
Sartorius plans to leverage NVIDIA solutions used in live-cell imaging platforms in drug discovery and in predictive bioprocessing designs.
Bolt Biotherapeutics shares fell 37% after shelving its lead candidate, pivoting its pipeline, halving its staff, and upending its C-suite.
The continuous glucose monitoring biosensor platform will use the funds to scale its manufacturing, move toward regulatory approval and perform more clinical trials.
Ajax Therapeutics has completed a $95 million financing, with plans to advance lead candidate AJ1‑11095 for myelofibrosis into the clinic.